TP53 and malignant colon neoplasm: The PRP4 activates p53 and inhibits E-cadherin (Figure 2D,E), suggesting that the specific PRP4–p53 protein interaction induces EMT and resistance to resveratrol and the eventual progression of colon cancer in vivo.